Cancer cell proliferation is inhibited by specific modulation frequencies

Br J Cancer · 2012 · Benefit · Low evidence

← Research stream

BenefitLow evidencePaper 6739

Study snapshot

PublicationBr J Cancer · 2012

Study typein_vitro

Reported directionBenefit

Evidence ratingLow

Abstract

Background: There is clinical evidence that very low and safe levels of amplitude-modulated electromagnetic fields administered via an intrabuccal spoon-shaped probe may elicit therapeutic responses in patients with cancer. However, there is no known mechanism explaining the anti-proliferative effect of very low intensity electromagnetic fields. Methods: To understand the mechanism of this novel approach, hepatocellular carcinoma (HCC) cells were exposed to 27.12 MHz radiofrequency electromagnetic fields using in vitro exposure systems designed to replicate in vivo conditions. Cancer cells were exposed to tumour-specific modulation frequencies, previously identified by biofeedback methods in patients with a diagnosis of cancer. Control modulation frequencies consisted of randomly chosen modulation frequencies within the same 100 Hz-21 kHz range as cancer-specific frequencies. Results: The growth of HCC and breast cancer cells was significantly decreased by HCC-specific and breast cancer-specific modulation frequencies, respectively. However, the same frequencies did not affect proliferation of nonmalignant hepatocytes or breast epithelial cells. Inhibition of HCC cell proliferation was associated with downregulation of XCL2 and PLP2. Furthermore, HCC-specific modulation frequencies disrupted the mitotic spindle. Conclusion: These findings uncover a novel mechanism controlling the growth of cancer cells at specific modulation frequencies without affecting normal tissues, which may have broad implications in oncology.

Machine Enhanced Logic

AI evidence extraction

Structured fields below were generated from the paper’s abstract and metadata to make the evidence easier to inspect. Automated extraction may be incomplete or incorrect; verify important details against the original paper.

Study typein_vitro

Effect directionbenefit

PopulationNot supplied

Sample sizeNot supplied

ExposureRF · 27.12 MHz

Evidence strengthLowConfidence: 74% · Peer reviewed: yes

Main findings

Hepatocellular carcinoma (HCC) and breast cancer cell growth was significantly decreased when exposed to their respective tumour-specific amplitude-modulation frequencies on a 27.12 MHz RF carrier, while the same frequencies did not affect proliferation of nonmalignant hepatocytes or breast epithelial cells. In HCC cells, inhibition was associated with downregulation of XCL2 and PLP2 and disruption of the mitotic spindle.

Outcomes measured

Cancer cell proliferation/growth
Proliferation of nonmalignant cells
Gene expression (XCL2, PLP2)
Mitotic spindle disruption

Limitations

In vitro study; findings may not translate to in vivo/clinical outcomes
Exposure duration not reported in abstract
Dose metrics (e.g., SAR/field strength) not reported in abstract
Sample size and replication details not reported in abstract
Tumour-specific modulation frequencies were identified by biofeedback methods in patients; details not provided in abstract

View raw extracted JSON

{
  "study_type": "in_vitro",
  "exposure": {
    "band": "RF",
    "source": null,
    "frequency_mhz": 27.12,
    "sar_wkg": null,
    "duration": null
  },
  "population": null,
  "sample_size": null,
  "outcomes": [
    "Cancer cell proliferation/growth",
    "Proliferation of nonmalignant cells",
    "Gene expression (XCL2, PLP2)",
    "Mitotic spindle disruption"
  ],
  "main_findings": "Hepatocellular carcinoma (HCC) and breast cancer cell growth was significantly decreased when exposed to their respective tumour-specific amplitude-modulation frequencies on a 27.12 MHz RF carrier, while the same frequencies did not affect proliferation of nonmalignant hepatocytes or breast epithelial cells. In HCC cells, inhibition was associated with downregulation of XCL2 and PLP2 and disruption of the mitotic spindle.",
  "effect_direction": "benefit",
  "limitations": [
    "In vitro study; findings may not translate to in vivo/clinical outcomes",
    "Exposure duration not reported in abstract",
    "Dose metrics (e.g., SAR/field strength) not reported in abstract",
    "Sample size and replication details not reported in abstract",
    "Tumour-specific modulation frequencies were identified by biofeedback methods in patients; details not provided in abstract"
  ],
  "evidence_strength": "low",
  "confidence": 0.74,
  "peer_reviewed_likely": "yes",
  "keywords": [
    "amplitude-modulated electromagnetic fields",
    "radiofrequency",
    "27.12 MHz",
    "modulation frequencies",
    "hepatocellular carcinoma",
    "breast cancer",
    "cell proliferation",
    "XCL2",
    "PLP2",
    "mitotic spindle"
  ],
  "suggested_hubs": []
}

AI can be wrong. Always verify against the paper.

AI-extracted fields are generated from the abstract and metadata and may be incomplete or incorrect. This material is for informational purposes and is not medical advice.

Identifiers and source

DOI: 10.1038/bjc.2011.523
PubMed: 22134506

Read the original paper →

Related papers

← Back to the Research Library